Drug intelligence / Profile preview

AT-003 (Adept Biopharmaceutical)

Development stage: Preclinical
Lead developer: Anpu Biomedical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AT-003 is a preclinical-stage bispecific antibody candidate developed by Adept Biopharmaceutical for the treatment of various solid tumors. Functioning within the immuno-oncology space, the molecule is engineered to simultaneously target two distinct antigens to enhance anti-tumor immune responses. Although the specific binding targets of AT-003 remain undisclosed by the company, the asset represents a key component of Adept's strategy to develop multi-specific biologics that overcome the limitations of traditional monoclonal antibodies in the tumor microenvironment.

Beyond the preview

Go deeper on AT-003 (Adept Biopharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-003 (Adept Biopharmaceutical).

Explore the full profile